Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028438 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT06028438 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 103 participants.
The verdict
NCT06028438, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.
Interventions
- DRUG Placebo
- DRUG Nipocalimab
- DRUG Certolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06028438
The ClinicalTrials.gov registry entry for NCT06028438 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06028438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06028438 about?
NCT06028438 is a clinical study titled "A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis". The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.
What is the current status of trial NCT06028438?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2023-08-15. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT06028438?
The interventions under investigation include: Placebo (DRUG), Nipocalimab (DRUG), Certolizumab (DRUG).
Who is sponsoring clinical trial NCT06028438?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.